Induced pluripotent stem cell (iPSC) technology has revolutionized the study of [neurodegenerative /diseases[/[diseases[/diseases, providing patient-derived cellular models that recapitulate disease-relevant phenotypes in ways that animal models cannot fully achieve. Since Shinya Yamanaka's Nobel Prize-winning discovery of cellular reprogramming in 2006, iPSC-derived neuronal and glial models have become indispensable tools for understanding disease mechanisms, identifying drug targets, and screening therapeutics for conditions including [Alzheimer [4]'s disease], [Parkinson's disease[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis (ALS)[/diseases/[als--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, and [frontotemporal dementia[/diseases/[ftd--TEMP--/diseases)--FIX-- (Okano et al., 2026).
iPSC disease modeling offers several critical advantages over traditional approaches: it preserves the patient's complete genetic background, enables the study of human-specific disease mechanisms, provides access to cell types that are otherwise inaccessible (such as [cortical pyramidal [neurons [5] and [dopaminergic [neurons[/entities/[neurons--TEMP--/entities)--FIX--[neurons[/entities//entities/, and reduces reliance on animal models. The integration of iPSC technology with [CRISPR gene editing[/treatments/[crispr-gene-editing--TEMP--/treatments)--FIX--, [brain organoids[/technologies/[brain-organoids--TEMP--/technologies)--FIX--, and high-throughput screening has further expanded the utility of these models for precision medicine and drug discovery (Li et al., 2024).
iPSCs are generated by introducing a defined set of transcription factors—typically OCT4, SOX2, KLF4, and c-MYC (the Yamanaka factors)—into somatic cells such as skin fibroblasts or peripheral blood mononuclear cells (PBMCs). Modern reprogramming protocols have moved beyond retroviral integration to use non-integrating methods including Sendai virus, episomal plasmids, modified mRNA, and small-molecule cocktails, reducing the risk of insertional mutagenesis and improving the safety profile of derived cells (Takahashi et al., 2006).
Quality control of iPSCs involves verification of pluripotency marker expression (NANOG, TRA-1-60, SSEA-4), karyotype stability, and confirmation of differentiation potential through trilineage differentiation assays. The International Stem Cell Initiative and the Induced Pluripotent Stem Cell Initiative (iPSCi) have established standardized protocols for iPSC generation and characterization (Marchetto et al., 2011).
iPSCs can be differentiated into virtually any neural cell type through carefully optimized protocols:
Cortical [neurons[/entities/[neurons--TEMP--/entities)--FIX--: Dual SMAD inhibition (SB431542 + LDN193189) followed by WNT inhibition to generate cortical progenitors, which mature into glutamatergic [neurons[/entities/[neurons--TEMP--/entities)--FIX-- relevant to [Alzheimer's disease[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and [frontotemporal dementia[/diseases/[ftd--TEMP--/diseases)--FIX--.
Dopaminergic [neurons[/entities/[neurons--TEMP--/entities)--FIX--: Floor plate-based differentiation using SHH agonists and FGF8 to generate midbrain dopaminergic [neurons[/entities/[neurons--TEMP--/entities)--FIX-- expressing [tyrosine hydroxylase], critical for modeling [Parkinson's disease[/diseases/[parkinsons--TEMP--/diseases)--FIX--.
Motor [neurons[/entities/[neurons--TEMP--/entities)--FIX--: Caudalization with retinoic acid and ventralization with SHH agonists to produce spinal motor [neurons[/entities/[neurons--TEMP--/entities)--FIX-- for [ALS[/diseases/[als--TEMP--/diseases)--FIX-- and [spinal muscular atrophy[/diseases/[spinal-muscular-atrophy--TEMP--/diseases)--FIX-- research.
[Astrocytes)/cell-types/[astrocytes): Extended differentiation protocols generating [GFAP[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX---positive cells that exhibit calcium signaling, glutamate uptake, and inflammatory responses.
[Oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX--: Protocols generating myelinating oligodendrocytes for studying [demyelination[/mechanisms/[demyelination--TEMP--/mechanisms)--FIX-- in [multiple sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- and leukodystrophies.
iPSC models have been instrumental in dissecting the complex pathobiology of [Alzheimer's disease[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Patient-derived [neurons[/entities/[neurons--TEMP--/entities)--FIX-- carrying mutations in [APP[/genes/[app--TEMP--/genes)--FIX--, [PSEN1)[/entities/[psen1--TEMP--/entities)--FIX--, and [PSEN2[/genes/[psen2--TEMP--/genes)--FIX-- recapitulate key disease features including increased [amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production (particularly the Aβ42/40 ratio), elevated tau] phosphorylation], endosomal enlargement, and altered [calcium signaling] (Bhatt et al., 2025).
Key findings from iPSC-based Alzheimer's research include:
APOE4 effects: iPSC-derived neurons and [astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- from [APOE4 show increased [Aβ[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production, impaired lipid metabolism, and enhanced inflammatory responses. Isogenic APOE3/APOE4 pairs generated by CRISPR editing have demonstrated that APOE4 impairs astrocyte-mediated [Aβ[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance and increases neuronal vulnerability to tau] pathology (Zhao et al., 2020, Nature Communications.
Amyloid processing: Patient neurons with familial AD mutations show elevated [BACE1[/entities/[bace1--TEMP--/entities)--FIX-- carrying mutations in [LRRK2[/genes/[lrrk2--TEMP--/genes)--FIX--, [SNCA)[/genes/[snca--TEMP--/genes)--FIX--, [PINK1[/genes/[pink1--TEMP--/genes)--FIX--, [PRKN[/genes/[prkn--TEMP--/genes)--FIX--, [GBA[/genes/[gba--TEMP--/genes)--FIX--, and [PARK7 (DJ-1)[/genes/[park7--TEMP--/genes)--FIX-- to reveal disease mechanisms:
[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--: The G2019S mutation, the most common genetic cause of PD, leads to increased kinase activity, impaired neurite outgrowth, and enhanced α-synuclein accumulation in iPSC-derived dopaminergic neurons.
[GBA1[/genes/[gba--TEMP--/genes)--FIX--: GBA-mutant iPSC neurons demonstrate [lysosomal dysfunction[/mechanisms/[lysosomal-dysfunction--TEMP--/mechanisms)--FIX--, glucocerebrosidase deficiency, and α-synuclein accumulation, connecting [Gaucher disease[/diseases/[gaucher-disease--TEMP--/diseases)--FIX-- biology to PD pathogenesis.
iPSC-derived [motor neurons[/cell-types/[motor-neurons--TEMP--/cell-types)--FIX-- from ALS patients carrying mutations in [SOD1[/proteins/[sod1-protein--TEMP--/proteins)--FIX--, [C9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--, [TARDBP[/genes/[tardbp--TEMP--/genes)--FIX--, and [FUS[/entities/[fus--TEMP--/entities)--FIX-- have revealed critical disease mechanisms (Fujimori et al., 2018):
iPSC models carrying expanded CAG repeats in the [HTT[/genes/[htt--TEMP--/genes)--FIX-- gene recapitulate features of [Huntington's disease[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, including [huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- protein/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- aggregation, transcriptional dysregulation, impaired BDNF signaling, and [medium spiny neuron[/cell-types/[medium-spiny-neurons--TEMP--/cell-types)--FIX-- vulnerability. These models have been particularly valuable for testing [antisense oligonucleotide[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX-- therapies targeting mutant [HTT[/genes/[htt--TEMP--/genes)--FIX-- mRNA.
iPSC models of [FTD[/diseases/[ftd--TEMP--/diseases)--FIX-- derived from patients with mutations in [MAPT[/genes/[mapt--TEMP--/genes)--FIX--, [GRN[/genes/[grn--TEMP--/genes)--FIX--, and [C9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- have provided insights into tau] pathology], [progranulin[/proteins/[progranulin--TEMP--/proteins)--FIX-- haploinsufficiency, and the convergent downstream mechanisms shared across FTD subtypes including [lysosomal dysfunction[/mechanisms/[lysosomal-dysfunction--TEMP--/mechanisms)--FIX-- and neuroinflammation.
Cerebral organoids—three-dimensional self-organized neural tissues derived from iPSCs—represent a major advance in modeling neurodegenerative diseases. These complex structures recapitulate aspects of human brain development and contain multiple neural cell types organized in layers reminiscent of cortical architecture. Recent advances include:
[CRISPR gene editing[/treatments/[crispr-gene-editing--TEMP--/treatments)--FIX-- has transformed iPSC disease modeling by enabling the creation of isogenic cell line pairs that differ only at a single genetic locus. This approach eliminates confounding genetic background effects and allows precise attribution of phenotypic changes to specific mutations. Applications include:
Neurodegenerative diseases involve complex interactions between neurons, glia, and immune cells. Advanced iPSC co-culture systems include:
Several compounds identified through iPSC-based screens have progressed to clinical trials. Notable examples include ropinirole for ALS (identified through iPSC motor neuron screening) and multiple LRRK2 kinase inhibitors validated in iPSC-derived dopaminergic neurons.
iPSC models enable patient-specific drug testing, identifying responders and non-responders before clinical treatment. This pharmacogenomic approach is particularly relevant for diseases with heterogeneous genetic bases, allowing stratification of patients for clinical trials and prediction of individual drug responses.
iPSC-derived neurons and cardiomyocytes enable early detection of neurotoxicity and cardiotoxicity in drug development pipelines, reducing late-stage clinical trial failures.
Despite their transformative potential, iPSC disease models face several important limitations:
Several major biobanks maintain collections of well-characterized iPSC lines for neurodegenerative disease research:
The field of iPSC disease modeling is evolving rapidly, with several emerging directions:
The study of Induced Pluripotent Stem Cell (Ipsc) Disease Models has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.